Skip to main content

Unveiling the Complexity of Neuroendocrine Neoplasms: Biomarkers, Classification, and Translational Perspectives

Cover image for Research Topic "Unveiling the Complexity of Neuroendocrine Neoplasms: Biomarkers, Classification, and Translational Perspectives"
49kviews
Editorial28 October 2026
Editorial: Unveiling the complexity of neuroendocrine neoplasms: biomarkers, classification, and translational perspectives

capture tumor evolution, biological subgroups, and prognostic heterogeneity, defining clinically relevant molecular classes of NENs. A second major theme is the shift toward clinically meaningful risk stratification. Although grade, stage, differentiation, and anatomical site remain essential prognostic factors in NENs, they do not fully capture disease complexity. The NUTRIGETNE study expands risk assessment in GEP-NENs by predicting malnutrition and sarcopenia [6], highlighting the relevance of nutritional status, muscle mass, and functional vulnerability for outcomes, treatment tolerance, quality of life, and long-term management. The same need for refined risk assessment emerges in functioning PanNETs such as insulinomas. The early prediction of malignancy using tumor size and biochemical markers addresses a clinically relevant problem: although most insulinomas behave indolently, the timely identification of aggressive potential remains challenging [7]. Combining anatomical and biochemical information may help distinguish patients who require closer surveillance and more individualized diagnostic pathways. Similarly, the recognition of bone metastases as a high-risk feature in metastatic NETs, particularly in NETs of unknown primary origin, highlights the prognostic relevance of disease distribution [8]. These studies suggest that risk stratification should increasingly integrate tumor biology, functional phenotype, disease burden, metastatic pattern, and host-related factors. The Research Topic highlights the biological and clinical determinants of NET development within specific tissue contexts. Type 1 gastric NETs associated with autoimmune atrophic gastritis exemplify the interplay between chronic inflammation, endocrine cell alterations, and the gastric microenvironment [9]. Integrating pathological context, host-related factors, and tumor biology may support individualized surveillance strategies and advance translational research. RWE is essential in rare tumors. The Italian Association for Neuroendocrine Tumors survey on pheochromocytomas and paragangliomas (PPGLs) reveals variability in diagnostic and clinical practice, highlighting the need for harmonization across centers [10]. RWE identifies gaps between guidelines, expert consensus, and daily practice, helping optimize biochemical testing, imaging, genetic assessment, multidisciplinary evaluation, and follow-up by assessing the implementation of classification and diagnostic principles in clinical settings. Collectively, this Research Topic highlights four converging directions in NEN research: biomarkerinformed classification incorporating tissue markers, receptor profiles, lineage factors, and nonconventional molecules [1][2][3]; molecular and epigenetic profiling to refine biological taxonomies [4,5]; prognostic stratification integrating grade, stage, nutritional status, biochemical phenotype, metastatic patterns, and disease-specific risk factors [6][7][8]; and translational models integrating pathology, molecular data, clinical phenotype, and RWE into reproducible, clinically applicable frameworks [9,10]. NEN complexity should be viewed as an opportunity for precision classification and individualized risk assessment. Future research should validate emerging biomarkers in large, well-annotated cohorts, integrate multi-omic data with histopathology, imaging, and clinical outcomes, develop robust predictive models, and harmonize diagnostic criteria across heterogeneous entities, supported by sustained multidisciplinary collaboration and patient-centered research networks. In conclusion, this Research Topic provides a timely synthesis of the evolving diagnostic, biological, and translational paradigms in NENs. The articles gathered here show that the future of NEN research lies in moving from fragmented descriptors toward integrated models of disease identity and risk. By combining morphology, biomarkers, molecular and epigenetic profiling, functional status, clinical phenotype, and RWE, the field can advance toward more precise classification, earlier recognition of aggressive behavior, and better-informed translational research.We sincerely thank all authors, reviewers, and the Frontiers editorial team for their valuable contributions to this Research Topic.

345 views

ORIGINAL RESEARCH
28 October 2026
Bone metastases identify a high-risk subgroup in metastatic neuroendocrine tumors with particular relevance in NETs of unknown primary
Annie Mathew, 5 more and Harald Lahner

498 views

ORIGINAL RESEARCH
1 October 2026
Methylation profiling reveals epigenetic programs associated with chr18 loss in small intestinal neuroendocrine tumors
Fredrik Axling, 3 more and Peter Stålberg

1,194 views

ORIGINAL RESEARCH
25 August 2026
Early prediction of metastatic insulinoma using tumor size and biochemical markers: a retrospective cohort study
Annie Mathew, 7 more and Harald Lahner

811 views

ORIGINAL RESEARCH
1 July 2026
Bone health in neuroendocrine tumors and prognostic implications beyond skeletal metastases
Andrea Casabella, 10 more and Manuela Albertelli

1,461 views

1 citations

ORIGINAL RESEARCH
7 July 2026
Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort
Roberta Elisa Rossi, 9 more and Alessandro Repici

2,548 views

ORIGINAL RESEARCH
26 May 2026
A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study
Maria Argente-Pla, 20 more and NUTRIGETNE GROUP

1,608 views

ORIGINAL RESEARCH
20 May 2026
Analysis of the efficacy and safety of endoscopic full-thickness resection in the treatment of rectal neuroendocrine tumors
Linzhen Li, 3 more and Yan Zhang

1,281 views

REVIEW
6 August 2026
Stathmin 1 across neuroendocrine neoplasms: biological, pathological and translational insights
Anna La Salvia, 6 more and Giuseppe Fanciulli

832 views

ORIGINAL RESEARCH
11 May 2026
Expression of ATRX, DAXX, PDX1, ARX, and somatostatin receptors in pancreatic neuroendocrine tumors: a clinicopathological study
Oana A. Ciobanu, 6 more and Carmen G. Barbu

2,414 views

REVIEW
1 May 2026
Targeting lineage-specific heterogeneity and hypovascular-fibrotic barriers may enable precision immunotherapy in pituitary neuroendocrine tumors
Jiayu Song, 5 more and Qiang Li

1,509 views

OPINION
13 April 2026
Rethinking the prognostic and biological significance of neuroendocrine marker expression in colorectal carcinoma
Alessandro Mangogna, 1 more and Massimo Milione

1,397 views

ORIGINAL RESEARCH
25 March 2026
Clinical analysis of seven cases of primary hepatic neuroendocrine neoplasms
Mengting Zhang, 2 more and Bingsong Yan

1,962 views

1 citations

ORIGINAL RESEARCH
18 December 2025
Case Report: Ectopic Cushing’s syndrome caused by a pancreatic neuroendocrine tumor managed through dual steroidogenesis inhibition and endoscopic ultrasound-guided ethanol ablation
Łukasz Krzystek, 9 more and Anhelli Syrenicz

3,131 views

3 citations

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial
CLINICAL TRIAL
1 December 2025
Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial
Maciej Kolodziej, 28 more and Grzegorz Kaminski
BackgroundPRRT with [177Lu]Lu-DOTA-TATE improves survival in advanced GEP-NETs, but fixed-activity dosing may result in undertreatment or unnecessary toxicity. Individualized dosimetry and tandem-PRRT with 90Y/177Lu have been proposed, but prospective randomized evidence is lacking.MethodsDUONEN is an ongoing multicenter, randomized phase 3 trial (N = 92 planned; 56 analyzed) comparing standard fixed-activity [177Lu]Lu-DOTA-TATE (arm A) with three dosimetry-guided regimens: arm B (177Lu+90Y, variable 90Y); arm C (177Lu+90Y, variable 177Lu); arm D (variable 177Lu). Organ dosimetry was performed after each cycle, with per-cycle activity modifications to respect kidney (23 Gy) and marrow (2 Gy) thresholds. Safety was assessed by laboratory, renal, and hepatic parameters.ResultsActivity reductions predominated in arms B and C, while increases were common in arm D. Median cumulative kidney and marrow doses were highest in arm C (29.1 Gy and 0.79 Gy, respectively), driven by 90Y contribution. Hematologic declines were observed across all arms, most prominently in lymphocytes and platelets, and correlated with marrow dose but not with categorical dose modifications. Renal function remained stable, and no clinically relevant hepatotoxicity occurred.ConclusionsThis interim analysis demonstrates the feasibility and safety of dosimetry-guided PRRT strategies, including individualized 177Lu escalation and tandem 90Y/177Lu. DUONEN provides the first randomized prospective evidence for isotope- and patient-tailored PRRT dosing. Long-term follow-up will clarify their impact on efficacy.Clinical trial registrationhttps://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-006068-99, identifier 2020-006068-99.

4,017 views

6 citations

CASE REPORT
5 December 2025
Case report: TP53 heterogeneous alteration in grade 3 type I gastric NET: a case implicating primary tumor progression
Yan Li, 4 more and Ying Dong

1,689 views

Pituitary hormone deficiencies in prolactinomas: prevalence, predictors, and functional recovery
ORIGINAL RESEARCH
10 November 2025
Pituitary hormone deficiencies in prolactinomas: prevalence, predictors, and functional recovery
Antonio Prinzi, 7 more and Pasqualino Malandrino
IntroductionTo evaluate the prevalence of pituitary hormone deficiencies in patients with prolactinomas, identify clinical and radiological predictors of non-gonadal hypopituitarism at diagnosis, and evaluate the potential for pituitary function recovery over long-term follow-up.MethodsWe conducted a retrospective multicenter study including 145 patients with prolactinomas diagnosed between 2000 and 2024 at two tertiary centers. All anterior pituitary axes were evaluated at diagnosis and during follow-up.ResultsAt diagnosis, 54 of 145 patients (37.2%) had at least one pituitary hormone deficiency. Hypogonadism was the most common deficit (34.5%), followed by non-gonadal hypopituitarism in 14.5%, including secondary adrenal insufficiency: 8.3%, central hypothyroidism: 7.6%, growth hormone deficiency (GHD): 6.9%. Macroadenomas were significantly more prevalent than microadenomas (25.8% vs. 2.7%, p<0.001). Tumor size was the only independent predictor of non-gonadal hypopituitarism at diagnosis (OR: 1.1, 95%CI: 1.03–1.20; p=0.007). ROC analysis identified 17 mm as the optimal cut-off to predict non-gonadal pituitary hormone deficiencies at diagnosis (sensitivity 84%, specificity 77%, AUC = 0.836). During follow-up (median 70 months), 66.7% of patients recovered at least one pituitary axis, with higher recovery in microadenomas (100% vs. 63.0%, p=0.038). Tumor size remained the strongest predictor of recovery (OR: 0.56, 95%CI: 0.34–0.94; p=0.029).ConclusionsNon-gonadal hypopituitarism is common in prolactinomas, especially larger tumors. Tumor size was the strongest predictor of both the presence and recovery of hormonal deficits, with an optimal cut-off of 17 mm. Long-term follow-up is essential, as many patients, especially those with smaller tumors, recover pituitary function after treatment, with gonadal and adrenal axes showing the highest likelihood.

2,797 views

4 citations

ORIGINAL RESEARCH
29 September 2025
Diagnosis and treatment of paragangliomas and pheochromocytomas: a survey from the Italian Association for Neuroendocrine Tumors
Erica Pietroluongo, 9 more and Salvatore Tafuto

3,597 views

3 citations

Management of type I gastric-neuroendocrine tumors: the less the better?
ORIGINAL RESEARCH
1 September 2025
Management of type I gastric-neuroendocrine tumors: the less the better?
Roberta Elisa Rossi, 9 more and Alessandro Repici

5,204 views

8 citations